ESR1 and breast cancer: In addition, our clinical pilot study (Phase II) has already shown that Doxycycline pre-treatment is effective in ER(+) breast cancer patients, for significantly reducing CSCs (by up to 66.67%), with a response rate of nearly 90% [35].